CRVS analyst estimates
Corvus Pharmaceuticals (CRVS) analyst ratings, the average price target and its range, and every firm's latest call.
CRVS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Mizuho Securities | Corvus Pharmaceuticals price target lowered to $27 from $30 at Mizuho | $27.00 |
| Apr 17, 2026 | Goldman Sachs | Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs | $40.00 |
| Jan 29, 2026 | Mizuho Securities | Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho | $30.00 |
| Jan 22, 2026 | Jefferies | Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies | $42.00 |
| Jan 21, 2026 | Oppenheimer | Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer | $32.00 |
| Jan 20, 2026 | H.C. Wainwright | Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright | $27.00 |
| Jan 20, 2026 | Mizuho Securities | Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho | $20.00 |
| Jan 20, 2026 | Barclays | Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays | $28.00 |
| Oct 29, 2025 | Mizuho Securities | Corvus Pharmaceuticals price target raised to $13 from $11 at Mizuho | $13.00 |
| Oct 13, 2025 | Barclays | Corvus Pharmaceuticals initiated with an Overweight at Barclays | $16.00 |
| May 20, 2025 | Mizuho Securities | Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho | $11.00 |
| Nov 13, 2024 | Jefferies | Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Jefferies | $13.00 |
| Oct 22, 2024 | Mizuho Securities | Mizuho Upgrades Corvus Pharmaceuticals (CRVS) to Outperform | $12.00 |
| Aug 18, 2023 | Oppenheimer | Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer | $7.00 |
- 5 firms rate CRVS: 5 buy, 0 hold, 0 sell.
- The average price target is $27.00 from 1 analysts, from $27.00 to $27.00.
Updated 2026-11-05 12:48 UTC